| Exec date | Filing date | Company | Role | Signal | Confidence | Shares | % of shares | Under plan? | Amount (USD) |
|---|---|---|---|---|---|---|---|---|---|
| Aug 13, 2024 | Aug 15, 2024 | Trade Desk, Inc. | Director | Sell | 15.0 | -150,000 | -50.52% | ✗ | $14.7M |
| Mar 8, 2024 | Mar 12, 2024 | Trade Desk, Inc. | Director | Sell | 16.3 | -103,030 | -26.04% | ✗ | $8.4M |
| Feb 6, 2023 | Feb 8, 2023 | Trade Desk, Inc. | Director | Sell | 52.5 | -21 | -0.01% | ✗ | $1.3K |
| Nov 30, 2022 | Dec 5, 2022 | Nuvation Bio Inc. | Director | Buy | 97.5 | +250,000 | 100.00% | ✗ | $483.8K |
| Nov 19, 2021 | Nov 23, 2021 | Trade Desk, Inc. | Director | Sell | 15.0 | -150,000 | -34.77% | ✗ | $16.3M |
| Mar 31, 2021 | Apr 2, 2021 | Arcus Biosciences, Inc. | Director | Buy | 97.5 | +20,000 | 12.30% | ✗ | $567K |
| Nov 19, 2020 | Nov 23, 2020 | Trade Desk, Inc. | Director | Sell | 15.0 | -20,000 | -31.93% | ✗ | $16.3M |
| Nov 11, 2019 | Nov 13, 2019 | Trade Desk, Inc. | Director | Sell | 16.3 | -29,786 | -41.80% | ✗ | $6.2M |
| Jun 13, 2019 | Jun 14, 2019 | Arcus Biosciences, Inc. | Director | Buy | 90.0 | +12,935 | 8.64% | ✗ | $110.2K |
| Jun 11, 2019 | Jun 13, 2019 | Arcus Biosciences, Inc. | Director | Buy | 95.0 | +20,000 | 15.42% | ✗ | $163.9K |
| Jun 7, 2019 | Jun 11, 2019 | Arcus Biosciences, Inc. | Director | Buy | 97.5 | +32,065 | 32.85% | ✗ | $258.8K |
| Mar 11, 2019 | Mar 13, 2019 | Trade Desk, Inc. | Director | Sell | 16.3 | -40,000 | -36.43% | ✗ | $8.2M |
| Sep 21, 2018 | Nov 30, 2018 | Trade Desk, Inc. | Director | Sell | 17.5 | -20,500 | -15.73% | ✗ | $2.7M |
| Mar 19, 2018 | Mar 19, 2018 | Arcus Biosciences, Inc. | Director | Buy | 97.5 | +30,000 | 59.40% | ✗ | $450K |
| Jun 15, 2017 | Jun 16, 2017 | Trade Desk, Inc. | Director | Buy | 97.5 | +20,000 | 20.00% | ✗ | $961.2K |
| Mar 1, 2017 | Mar 3, 2017 | Trade Desk, Inc. | Director | Buy | 97.5 | +20,000 | 25.00% | ✗ | $867.7K |
| Aug 12, 2013 | Aug 14, 2013 | HALOZYME THERAPEUTICS, INC. | Director | Buy | 97.5 | +100,000 | 55.56% | ✗ | $681.6K |
| Nov 13, 2012 | Nov 14, 2012 | HALOZYME THERAPEUTICS, INC. | Director | Buy | 97.5 | +50,000 | 45.45% | ✗ | $260.5K |
| Jun 16, 2009 | Jun 17, 2009 | Oruka Therapeutics, Inc. | CFO | Sell | 22.5 | -21,000 | -100.00% | ✗ | $75.9K |